Spironolactone Safety in Dialysis Patients

Withdrawn before enrolling · Phase 4

Conditions studied: End Stage Renal Disease, Congestive Heart Failure

In brief

Cardiovascular disease is the leading cause of death and disproportionately prevalent in patients with kidney disease. Spironolactone has been shown to improve survival in the general population with heart failure by up to 30%. We wish to study the safety and tolerability of aldosterone blockade with spironolactone on cardiac function in a high risk population of patients on hemodialysis. We will study and closely monitor subjects over a period of 12 months, during which they will be receiving spironolactone for a period of 6 months.

Key facts

Study ID

NCT00328809

Run by

State University of New York - Upstate Medical University

People needed

0

Starts

2013-06-30

Expected to finish

2019-09-24

Last updated by the study team

2020-10-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• They must be at least 18 years of age.
• They must understand the study purpose and give their written informed consent.
• They must have been stable on chronic hemodialysis for at least three months before enrollment into the study.
• Hemodialysis subjects will be included if they have had a left ventricular ejection fraction measured within the past six months with a value no more than 45 percent. A repeat, standardized echocardiogram will be used to confirm left ventricular ejection fraction.

You may not qualify if…

• Subjects with primary operable valvular heart disease.
• Subjects with a congenital heart disease.
• Subjects with unstable angina.
• Subjects with primary hepatic failure.
• Subjects with active cancer or any life-threatening disease (other than heart failure or end-stage renal disease).
• Subjects who have undergone heart transplantation or who are awaiting heart transplantation are also ineligible.
• Subjects on a renal transplant list will be accepted into the study until the time of successful renal transplantation and termination of dialysis.
• Subjects with habitually difficult to control hyperkalemia (serum potassium >6.0 meq/L) in the previous month while on dialysis will be excluded.
• The inability to complete the 6-minute walk test will not be a reason to exclude subjects from this study.

Where it is running

• SUNY Upstate Medical University — Syracuse, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.